18-Hydroxycorticosterone: 11 beta,18,21-Trihydroxypregn-4-ene-3,20-dione.Hypothyroidism: A syndrome that results from abnormally low secretion of THYROID HORMONES from the THYROID GLAND, leading to a decrease in BASAL METABOLIC RATE. In its most severe form, there is accumulation of MUCOPOLYSACCHARIDES in the SKIN and EDEMA, known as MYXEDEMA.Thyroxine: The major hormone derived from the thyroid gland. Thyroxine is synthesized via the iodination of tyrosines (MONOIODOTYROSINE) and the coupling of iodotyrosines (DIIODOTYROSINE) in the THYROGLOBULIN. Thyroxine is released from thyroglobulin by proteolysis and secreted into the blood. Thyroxine is peripherally deiodinated to form TRIIODOTHYRONINE which exerts a broad spectrum of stimulatory effects on cell metabolism.18-Hydroxydesoxycorticosterone: An analog of desoxycorticosterone which is substituted by a hydroxyl group at the C-18 position.Congenital Hypothyroidism: A condition in infancy or early childhood due to an in-utero deficiency of THYROID HORMONES that can be caused by genetic or environmental factors, such as thyroid dysgenesis or HYPOTHYROIDISM in infants of mothers treated with THIOURACIL during pregnancy. Endemic cretinism is the result of iodine deficiency. Clinical symptoms include severe MENTAL RETARDATION, impaired skeletal development, short stature, and MYXEDEMA.Steroid 11-beta-Hydroxylase: A mitochondrial cytochrome P450 enzyme that catalyzes the 11-beta-hydroxylation of steroids in the presence of molecular oxygen and NADPH-FERRIHEMOPROTEIN REDUCTASE. This enzyme, encoded by CYP11B1 gene, is important in the synthesis of CORTICOSTERONE and HYDROCORTISONE. Defects in CYP11B1 cause congenital adrenal hyperplasia (ADRENAL HYPERPLASIA, CONGENITAL).Hyperthyroidism: Hypersecretion of THYROID HORMONES from the THYROID GLAND. Elevated levels of thyroid hormones increase BASAL METABOLIC RATE.Corticosterone: An adrenocortical steroid that has modest but significant activities as a mineralocorticoid and a glucocorticoid. (From Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th ed, p1437)Aldosterone: A hormone secreted by the ADRENAL CORTEX that regulates electrolyte and water balance by increasing the renal retention of sodium and the excretion of potassium.Aldosterone Synthase: A mitochondrial cytochrome P450 enzyme that catalyzes the 18-hydroxylation of steroids in the presence of molecular oxygen and NADPH-specific flavoprotein. This enzyme, encoded by CYP11B2 gene, is important in the conversion of CORTICOSTERONE to 18-hydroxycorticosterone and the subsequent conversion to ALDOSTERONE.Adrenal Glands: A pair of glands located at the cranial pole of each of the two KIDNEYS. Each adrenal gland is composed of two distinct endocrine tissues with separate embryonic origins, the ADRENAL CORTEX producing STEROIDS and the ADRENAL MEDULLA producing NEUROTRANSMITTERS.Benzphetamine: A sympathomimetic agent with properties similar to DEXTROAMPHETAMINE. It is used in the treatment of obesity. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1222)Fetus: The unborn young of a viviparous mammal, in the postembryonic period, after the major structures have been outlined. In humans, the unborn young from the end of the eighth week after CONCEPTION until BIRTH, as distinguished from the earlier EMBRYO, MAMMALIAN.Adrenal Cortex: The outer layer of the adrenal gland. It is derived from MESODERM and comprised of three zones (outer ZONA GLOMERULOSA, middle ZONA FASCICULATA, and inner ZONA RETICULARIS) with each producing various steroids preferentially, such as ALDOSTERONE; HYDROCORTISONE; DEHYDROEPIANDROSTERONE; and ANDROSTENEDIONE. Adrenal cortex function is regulated by pituitary ADRENOCORTICOTROPIN.Adrenocorticotropic Hormone: An anterior pituitary hormone that stimulates the ADRENAL CORTEX and its production of CORTICOSTEROIDS. ACTH is a 39-amino acid polypeptide of which the N-terminal 24-amino acid segment is identical in all species and contains the adrenocorticotrophic activity. Upon further tissue-specific processing, ACTH can yield ALPHA-MSH and corticotrophin-like intermediate lobe peptide (CLIP).Adrenal Gland Neoplasms: Tumors or cancer of the ADRENAL GLANDS.Pregnancy Trimester, Second: The middle third of a human PREGNANCY, from the beginning of the 15th through the 28th completed week (99 to 196 days) of gestation.Pregnancy: The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.Hydrocortisone: The main glucocorticoid secreted by the ADRENAL CORTEX. Its synthetic counterpart is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions.Databases, Chemical: Databases devoted to knowledge about specific chemicals.Databases, Pharmaceutical: Databases devoted to knowledge about PHARMACEUTICAL PRODUCTS.Kidney: Body organ that filters blood for the secretion of URINE and that regulates ion concentrations.Pharmacological Processes: The metabolism of drugs and their mechanisms of action.Electrolytes: Substances that dissociate into two or more ions, to some extent, in water. Solutions of electrolytes thus conduct an electric current and can be decomposed by it (ELECTROLYSIS). (Grant & Hackh's Chemical Dictionary, 5th ed)Water: A clear, odorless, tasteless liquid that is essential for most animal and plant life and is an excellent solvent for many substances. The chemical formula is hydrogen oxide (H2O). (McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed)Adenoma: A benign epithelial tumor with a glandular organization.Reproducibility of Results: The statistical reproducibility of measurements (often in a clinical context), including the testing of instrumentation or techniques to obtain reproducible results. The concept includes reproducibility of physiological measurements, which may be used to develop rules to assess probability or prognosis, or response to a stimulus; reproducibility of occurrence of a condition; and reproducibility of experimental results.Sensitivity and Specificity: Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)Retinal Neoplasms: Tumors or cancer of the RETINA.Chromatography, Liquid: Chromatographic techniques in which the mobile phase is a liquid.Tandem Mass Spectrometry: A mass spectrometry technique using two (MS/MS) or more mass analyzers. With two in tandem, the precursor ions are mass-selected by a first mass analyzer, and focused into a collision region where they are then fragmented into product ions which are then characterized by a second mass analyzer. A variety of techniques are used to separate the compounds, ionize them, and introduce them to the first mass analyzer. For example, for in GC-MS/MS, GAS CHROMATOGRAPHY-MASS SPECTROMETRY is involved in separating relatively small compounds by GAS CHROMATOGRAPHY prior to injecting them into an ionization chamber for the mass selection.Calibration: Determination, by measurement or comparison with a standard, of the correct value of each scale reading on a meter or other measuring instrument; or determination of the settings of a control device that correspond to particular values of voltage, current, frequency or other output.Reference Standards: A basis of value established for the measure of quantity, weight, extent or quality, e.g. weight standards, standard solutions, methods, techniques, and procedures used in diagnosis and therapy.
(1/16) Aldosterone synthase deficiency type I with no documented homozygous mutations in the CYP11B2 gene.

This case report concerns a girl born from non-consanguineous parents and hospitalized in another hospital at the age of 14 days because of a severe salt-losing syndrome (Na=125, K=8.6 mEq/l). In spite of normal genitalia, diagnosis of 21-hydroxylase deficiency was assessed on the basis of a slightly increased 17-OH-progesterone serum level (6.4 ng/ml). The onset of both hydrocortisone and 9alpha-fluorohydrocortisone therapy was followed by a resolution of the clinical picture. At the age of 60 days she was admitted to our clinic for a re-evaluation of the diagnosis. Steroid hormone serum levels were measured after withdrawal of therapy and diagnosis of corticosterone methyl oxidase (CMO) deficiency type I was definitely established in the light of the biochemical results: i.e. very low 18-hydroxycorticosterone (18-OH-B) serum levels (20 pg/ml), an abnormally high corticosterone/18-OH-B serum ratio (306.5) and an abnormally low 18-OH-B/aldosterone serum ratio (2.1). This autosomal recessively inherited disorder can be differentiated from CMO type II and other salt-wasting syndromes only on the basis of the serum steroid hormone pattern. After establishing the diagnosis of CMO I deficiency, hydrocortisone therapy was withdrawn whilst treatment with 9alpha-fluorohydrocortisone was begun again, with a satisfactory clinical and metabolic impact. Direct sequences of the patient's DNA were able to identify only a (heterozygous) amino acid substitution in exon 7 of that gene, which is known to have only a small effect on enzyme activity and cannot be the only cause of the patient's phenotype: valine-386-alanine (V386A) GTG-->GcG. No homozygous mutations in the CYP11B2 gene were observed. This is the first report of a patient with CMO type I who does not carry any homozygous mutation in the entire CYP11B2 alleles, whereas some cases with no mutations in this gene have already been reported in CMO II. The present study seems to be inconsistent with the previously reported correlation of the phenotype and genotype in CMO type I. A reasonable question that might be raised on the basis of our findings in this case report is whether other genes, apart from CYP11B2, are involved in the regulation of terminal aldosterone synthesis.  (+info)

(2/16) Mutations in aldosterone synthase gene of Milan hypertensive rats: phenotypic consequences.

Using in vitro and in vivo methods, we have demonstrated increased sensitivity of adrenocortical steroidogenesis to ACTH in Milan hypertensive (MHS) compared with normotensive (MNS) rats and have investigated whether this is caused by mutations of steroidogenic enzymes. Genes encoding aldosterone synthase (CYP11B2) and 11beta-hydroxylase (CYP11B1) in MHS and MNS have been cloned and sequenced. Nucleotide 752 (G) in exon 4 of MHS CYP11B2 differs from that of MNS (A); CYP11B1 sequences were identical. The nucleotide 752 mutation caused a Q251R substitution in the amino acid sequence of MHS CYP11B2. The phenotype of MHS CYP11B2 alleles, when expressed in COS-1 cells, differed from that of MNS alleles. The relative activities of the three reactions catalyzed by CYP11B2 (11beta-hydroxylation of deoxycorticosterone, 18-hydroxylation of corticosterone, and dehydrogenation of 18-hydroxycorticosterone) were estimated after incubation of transfected cells with [(14)C]deoxycorticosterone and analysis of radioactivity associated with deoxycorticosterone, corticosterone, 18 hydroxycorticosterone, and aldosterone. Both 11- and 18-hydroxylase activities were lower (19 and 12%, respectively; P < 0.01 and P < 0.05) in cells transfected with MHS compared with MNS alleles, whereas 18-oxidase activity was 42% higher (P < 0.01). To assess the significance of the CYP11B2 mutation in vivo, DNA from F2 hybrid MHS x MNS rats was genotyped. MHS alleles were associated with lower urine volumes in both sexes, lower ventricle weights in male rats, but no difference in systolic or diastolic blood pressures between the sexes. We conclude that a mutation in CYP11B2 may affect aldosterone secretion in MHS; however, under normal environmental circumstances, we were unable to demonstrate any influence of this mutation on blood pressure.  (+info)

(3/16) Stereological and functional investigations on isolated adrenocortical cells. III. Zona glomerulosa cells of chronically ACTH-treated rats.

Prolonged (5 day) treatment of rats with high doses of ACTH caused a significant reduction in the plasma concentration of aldosterone and a notable rise in that of corticosterone. Outer subcapsular (zona glomerulosa [ZG]) adrenocortical cells were isolated, and their morphology and secretory activity was investigated. ACTH pretreatment induced a marked hypertrophy of ZG cells which was coupled with significant increases in the volume of the mitochondrial compartment and in the surface area per cell of mitochondrial cristae and AER tubules, as well as with a striking lipid droplet depletion. Mitochondrial cristae were found to change from a tubulo-laminar to a tubulo-convolute configuration. Despite their hypertrophy, ZG cells from ACTH-pretreated rats displayed a conspicuous decrease in both basal and stimulated overall production of post-pregnenolone steroids, which was ascribed to the depletion of their stores of steroid hormone precursors (i.e. cholesterol and cholesterol esters contained in the lipid droplets). However, both basal and stimulated secretion of aldosterone was doubled, suggesting that chronic ACTH treatment induces in ZG cells an increased availability of monoxygenase II, the enzyme involved in the transformation of 18-hydroxycorticosterone into aldosterone. In the light of these findings, the drop in the plasma level of aldosterone observed in rats after prolonged treatment with ACTH is assumed to be due to an enhanced metabolism of aldosterone, possibly at the hepatic level.  (+info)

(4/16) Altered responses of plasma 18-hydroxycorticosterone and aldosterone to angiotensin II and adrenocorticotropin in patients with a 18-hydroxycorticosterone-producing tumor.

Plasma 18-hydroxycorticosterone (18-OHB) and aldosterone responses to angiotensin II (AII) and ACTH were examined in 2 patients with a 18-OHB-producing tumor (18-OHBPT) versus those in 8 patients with a aldosterone-producing adenoma (APA), 7 patients with low renin essential hypertension (LREH) and 10 normal subjects. Plasma 18-OHB and aldosterone levels and the 18-OHB: aldosterone ratio were high in patients with an APA and normal in patients with LREH. In patients with a 18-OHBPT, plasma 18-OHB and aldosterone levels were high and normal, respectively, resulting in a 2-fold greater 18-OHB: aldosterone ratio than that in patients with an APA. Patients with an APA had a blunted response of plasma 18-OHB and aldosterone to AII and a supranormal response of these corticoids to ACTH. Patients with LREH had a supranormal response of plasma 18-OHB and aldosterone to AII and a normal response of these corticoids to ACTH. In patients with a 18-OHBPT the responses of both plasma 18-OHB and aldosterone to AII and ACTH closely resembled those in patients with an APA but not in patients with LREH. These data suggest that 18-OHBPT may be a variant of aldosteronomas, producing a large amount of 18-OHB and a small amount of aldosterone.  (+info)

(5/16) Effects of corticotropin-releasing factor (CRF) on aldosterone and 18-hydroxycorticosterone in essential hypertension and primary aldosteronism.

The effects of ovine corticotropin releasing factor (o-CRF) on plasma aldosterone, 18-OH-corticosterone (18-OHB), plasma adrenocorticotropin (ACTH) and cortisol were determined in eight patients with primary aldosteronism, six with aldosterone-producing adenoma (APA) and two with idiopathic hyperaldosteronism (IHA). The results were compared with those in six normal subjects and eleven patients with essential hypertension (EHT, 5 with low renin and 6 with normal renin). In patients with APA, the peak plasma aldosterone and 18-OHB responses to 100 micrograms iv of o-CRF (226% and 113% increase from baseline, respectively) were greater than those in EHT and normal subjects. The net integrated aldosterone and 18-OHB responses (840 +/- 156, and 419 +/- 121 ng/dl.hr, respectively) were also significantly greater (p less than 0.01) in APA than those in normals and EHT. In two patients with IHA, both the peak and net integrated aldosterone response were smaller than those in APA, in spite of nearly identical plasma ACTH and cortisol responses. These results suggest that augmented responses of mineralocorticoids to o-CRF may be characteristic of aldosteronism due to APA, mediated by CRF-induced ACTH, and possibly other proopiomelanocortin (POMC)-derived peptides.  (+info)

(6/16) The renal, cardiovascular and hormonal actions of human atrial natriuretic peptide in man; effects of indomethacin.

The renal, cardiovascular and hormonal effects of intravenous infusion of alpha-human atrial natriuretic polypeptides (alpha-hANP) at the concentrations of 0.0125, 0.025, 0.05, 0.1 microgram kg-1 min-1 for 20 min was studied in six male volunteers before and after indomethacin administration (150 mg day-1, three times daily for 3 days). Dose-dependent diuresis and natriuresis were observed in all subjects between the concentrations of 0.025 and 0.1 microgram kg-1 min-1, which were not influenced by indomethacin. Diastolic blood pressure decreased significantly (P less than 0.05) at the higher dose (0.05 microgram kg-1 min-1) of alpha-hANP, which was attenuated by indomethacin pretreatment. The plasma concentration of the immunoreactive alpha-hANP was 73.7 +/- 25 pg ml-1 on the control in subjects taking 200 mEq day-1 of sodium, and significant diuresis occurred when plasma concentration reached approximately 330.5 +/- 74.4 pg ml-1. alpha-hANP infusion caused a dose-dependent increase in cyclic GMP, no significant changes in plasma aldosterone and 18-hydroxycorticosterone, which were not influenced by indomethacin pretreatment. Plasma renin did not change in response to alpha-hANP infusion, which was significantly decreased (P less than 0.05) after indomethacin pretreatment. These results support that the renal effects of alpha-hANP may be exerted by prostaglandin-independent mechanisms. The renal effects occur at lower doses, and cardiovascular changes occur at higher doses of alpha-hANP.  (+info)

(7/16) An adrenocortical tumor secreting weak mineralocorticoids.

An adrenocortical carcinoma (15.5 g) secreting excessive amounts of steroids with weak mineralocorticoid activity in a 25-year-old woman was studied with particular reference to its in vivo and in vitro secretions of steroids. Severe hypertension, occasional low serum potassium and suppressed PRA were the major clinical findings, and were improved with removal of the tumor. In the preoperative stage, plasma levels of 11-deoxycorticosterone, 18-hydroxy-11-deoxycorticosterone, corticosterone and 18-hydroxycorticosterone were all increased. However, the plasma level of aldosterone was repeatedly normal. Although plasma levels of pregnenolone, 17-hydroxypregnenolone, progesterone and 17-hydroxyprogesterone were very high, those of other late step steroids, i.e. 11-deoxycortisol, cortisol, dehydroepiandrosterone, androstenedione and testosterone were almost normal. From these findings, a major etiological role of weak mineralocorticoids such as 11-deoxycorticosterone, 18-hydroxycorticosterone and corticosterone in her hypertension was suggested. Pregnenolone and 17-hydroxypregnenolone in tumor tissue were increased, but 11-deoxycorticosterone, corticosterone, aldosterone, cortisol and adrenal androgens such as dehydroepiandrosterone, androstenedione and testosterone were below normal or low normal. In vitro production of 11-deoxycorticosterone, aldosterone or cortisol by the tumor tissue slices was very low and scarcely responded to synthetic ACTH.  (+info)

(8/16) Adrenal steroid responses to ACTH in glucocorticoid-suppressible aldosteronism.

To investigate adrenal responses to adrenocorticotrophin (ACTH), we infused graded doses of ACTH (1.25 to 20.0 mIU/30 minutes) in normal subjects, patients with low-renin essential hypertension (LREH), primary aldosteronism (PA), and glucocorticoid-suppressible hyperaldosteronism (GSH). Plasma aldosterone, cortisol, corticosterone, and 18-hydroxycorticosterone were measured. The results revealed a greater increase in the plasma aldosterone and 18-hydroxycorticosterone levels evoked by ACTH in the GSH group than in any other group, which suggested enhanced responsiveness of the aldosterone-producing cells to ACTH and a probable adrenal abnormality.  (+info)

*  18-Hydroxycorticosterone
... is a derivative of corticosterone. It serves as an intermediate in the synthesis of aldosterone by the ...
*  List of steroid abbreviations
18 (1): 117-24. doi:10.1046/j.1460-9568.2003.02734.x. PMID 12859344. Labrie C, Simard J, Zhao HF, Belanger A, Pelletier G, ... 2007). "Measurement of 18-Hydroxycorticosterone During Adrenal Vein Sampling for Primary Aldosteronism". Journal of Clinical ...
*  C21H30O5
The molecular formula C21H30O5 (molar mass: 362.46 g/mol, exact mass: 362.209324) may refer to: Cortisol, a corticosteroid Dihydrocortisone Humulone 18-Hydroxycorticosterone ...
*  Aldosterone synthase
The corticosterone methyl oxidase deficiencies both share this effect however type I causes an overall deficiency of 18- ... hydroxycorticosterone while type II overproduces it. Inhibition of aldosterone synthase is currently being investigated as a ... 1992). "Role of steroid 11 beta-hydroxylase and steroid 18-hydroxylase in the biosynthesis of glucocorticoids and ... Aldosterone synthase converts 11-deoxycorticosterone to corticosterone, to 18-hydroxycorticosterone, and finally to aldosterone ...
*  Cortisol
18 (1): 41-78. doi:10.1089/vim.2005.18.41. PMC 1224723 . PMID 15802953. Lovallo WR, Farag NH, Vincent AS, Thomas TL, Wilson MF ... 18 (4): 301-9. PMID 3084123. Mikosha AS, Pushkarov IS, Chelnakova IS, Remennikov GY (1991). "Potassium Aided Regulation of ... I 18-hydroxylation and 18hydroxy dehydrogenation. II beta-hydroxylation". Acta Endocrin. Copenh. 69: I 701-717, II 718-730. ... "The effect of sodium deprivation and of angiotensin II infusion on the peripheral plasma concentrations of 18- ...
*  List of corticosteroids
18-hydroxypregn-4-ene-3,20-dione [5] 21-Deoxycortisol = 11β,17α-dihydroxypregn-4-ene-3,20-dione, 21-Deoxycortisone = 17α- ... 18,20-trione Corticosterone (17-deoxycortisol) = 11β,21-dihydroxypregn-4-ene-3,20-dione Cortisol (hydrocortisone) = 11β,17α,21- ... 18,21-dihydroxypregn-4-ene-3,20-dione [4] 18-Hydroxycorticosterone = 11β,18,21-trihydroxypregn-4-ene-3,20-dione 18- ...
*  Corticosterone 18-monooxygenase
In enzymology, a corticosterone 18-monooxygenase (EC 1.14.15.5) is an enzyme that catalyzes the chemical reaction ... The systematic name of this enzyme class is corticosterone,reduced-adrenal-ferredoxin:oxygen oxidoreductase (18-hydroxylating ... 18-hydroxycorticosterone + oxidized adrenal ferredoxin + H2O The 3 substrates of this enzyme are corticosterone, reduced ... whereas its 3 products are 18-hydroxycorticosterone, oxidized adrenal ferredoxin, and H2O. This enzyme belongs to the family of ...
*  List of MeSH codes (D06)
18-hydroxydesoxycorticosterone MeSH D06.472.040.585.745 --- pregnenolone MeSH D06.472.040.585.745.500 --- 17-alpha- ... 18-hydroxycorticosterone MeSH D06.472.040.585.353.825 --- tetrahydrocortisol MeSH D06.472.040.585.478 --- 17- ...
*  List of MeSH codes (D04)
18-hydroxycorticosterone MeSH D04.808.745.745.654.252 --- cortodoxone MeSH D04.808.745.745.654.339 --- desoxycorticosterone ... MeSH D04.808.745.745.654.339.400 --- 18-hydroxydesoxycorticosterone MeSH D04.808.745.745.654.473 --- flurandrenolone MeSH ...
17ß-hydroxycorticosterone synonyms, 17ß-hydroxycorticosterone antonyms - FreeThesaurus.com  17ß-hydroxycorticosterone synonyms, 17ß-hydroxycorticosterone antonyms - FreeThesaurus.com
Antonyms for 17ß-hydroxycorticosterone. 3 synonyms for cortisol: Cortef, hydrocortisone, Hydrocortone. What are synonyms for ... redirected from 17ß-hydroxycorticosterone). Also found in: Dictionary, Medical, Encyclopedia. #vtZoom,.vt-link{cursor:pointer ... 17ß-hydroxycorticosterone synonyms, 17ß-hydroxycorticosterone antonyms - FreeThesaurus.com https://www.freethesaurus.com/17%c3% ... 9f-hydroxycorticosterone',FreeThesaurus.com,/a,,/div, ,!--End of Graphic Thesaurus by FreeThesaurus.com--,. The code for ...
more infohttps://www.freethesaurus.com/17%C3%9F-hydroxycorticosterone
18-hydroxycorticosterone (CHEBI:16485)  18-hydroxycorticosterone (CHEBI:16485)
CHEBI:16485 - 18-hydroxycorticosterone. Main. ChEBI Ontology. Automatic Xrefs. Reactions. Pathways. Models. ... 18-hydroxycorticosterone (CHEBI:16485) is a 3-oxo steroid (CHEBI:47788) 18-hydroxycorticosterone (CHEBI:16485) is a primary α- ... 18-hydroxycorticosterone (CHEBI:16485) is a 11β-hydroxy steroid (CHEBI:35346) 18-hydroxycorticosterone (CHEBI:16485) is a 18- ... 18-hydroxycorticosterone (CHEBI:16485) is a 20-oxo steroid (CHEBI:36885) 18-hydroxycorticosterone (CHEBI:16485) is a 21-hydroxy ...
more infohttps://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:16485
18-Hydroxycorticosterone - Wikipedia  18-Hydroxycorticosterone - Wikipedia
18-Hydroxycorticosterone is a derivative of corticosterone. It serves as an intermediate in the synthesis of aldosterone by the ...
more infohttps://en.wikipedia.org/wiki/18-Hydroxycorticosterone
18 hydroxycorticosterone - Answers on HealthTap  18 hydroxycorticosterone - Answers on HealthTap
I have a question if my due date is may 18 2013 and last menstrual was august 11 what day did i conceive? I will be exactly 3 ... On day 18 of bydureon (exenatide) with higher sugars. Shouldn't i see an improvement by now? ... 18 years with high cholesterol, hyperlipidema, can we give Milo with pastuerised milk once a day ? ... I'm 18, and I have a hunch back is their anyway I can fix it? ... 18 What is the purpose of an mmpi? And how do you interprit the ...
more infohttps://www.healthtap.com/topics/18-hydroxycorticosterone
DISTINCTIVE PLASMA-ALDOSTERONE, 18-HYDROXYCORTICOSTERONE, and 18-HYDROXYDEOXYCORTICOSTERONE PROFILE in the 21-HYDROXYLASE, 17...  DISTINCTIVE PLASMA-ALDOSTERONE, 18-HYDROXYCORTICOSTERONE, and 18-HYDROXYDEOXYCORTICOSTERONE PROFILE in the 21-HYDROXYLASE, 17...
DISTINCTIVE PLASMA-ALDOSTERONE, 18-HYDROXYCORTICOSTERONE, and 18-HYDROXYDEOXYCORTICOSTERONE PROFILE in the 21-HYDROXYLASE, 17- ... DISTINCTIVE PLASMA-ALDOSTERONE, 18-HYDROXYCORTICOSTERONE, and 18-HYDROXYDEOXYCORTICOSTERONE PROFILE in the 21-HYDROXYLASE, 17- ...
more infohttp://repositorio.unifesp.br/handle/11600/24912
LIPID MAPS Lipid Structure Database (LMSD) : LIPID MAPS Lipidomics Gateway  LIPID MAPS Lipid Structure Database (LMSD) : LIPID MAPS Lipidomics Gateway
18-Hydroxycorticosterone (W). 11β,18,21-trihydroxy-pregn-4-ene-3,20-. dione. C21H30O5. 362.2093. ... 13-ethyl-17α-hydroxy-18,19-dinorpregn-. 4-en-20-yn-3-one. C21H28O2. 312.2089. ... 13-ethyl-11-methylene-18,19-dinorpregn-. 4-en-20-yn-17α-ol. C22H30O. 310.2297. ... 18xi,21-dihydroxy-11β,18-epoxypregn-4-. ene-3,20-dione. C21H28O5. 360.1937. ...
more infohttp://lipidmaps.org/data/structure/LMSDSearch.php?Mode=ProcessClassSearch&LMID=LMST0203
Classical pathway of steroidogenesis, including diseases (Homo sapiens) - WikiPathways  Classical pathway of steroidogenesis, including diseases (Homo sapiens) - WikiPathways
18-hydroxycorticosterone. 17-beta-HSD3. Cholesterol. 11beta-HSD2. Oestradiol. 3-beta-HSD. P450c11. P450c17. P450c17. 3-beta-HSD ... 18. P450 oxidoreductase deficiency. 15. 19. 3-beta-HSD type II deficiency. 13. POR. Progesterone resistance. Oestrogen ... 15:18, 17 February 2019. DeSl. Changed arrows for diseases to graphical lines; small layout changes.. 103196. view. 15:36, 15 ... 18-hydroxycorticosterone. mim-conversion. RHEA:11873 (Rhea) Cortisol. Cortisone. mim-conversion. RHEA:53117 (Rhea) Cortisone. ...
more infohttps://www.wikipathways.org/index.php?title=Pathway:WP4523&oldid=103565&printable=yes
Classical pathway of steroidogenesis, including diseases (Homo sapiens) - WikiPathways  Classical pathway of steroidogenesis, including diseases (Homo sapiens) - WikiPathways
18-hydroxycorticosterone. Cortisol. 3-beta-HSD. 11beta-HSD1. Testosterone. POR. STAR. Pregnenolone. H6PD. Corticosterone. ... 18. Lipoid adrenal hyperplasia. 12. Cytochrome b5. P450scc. P450c21. Dihydrotestosterone. 17-hydroxyprogesterone. P450c17. 11- ... 15:18, 17 February 2019. DeSl. Changed arrows for diseases to graphical lines; small layout changes.. 103196. view. 15:36, 15 ... 18-hydroxycorticosterone. mim-conversion. RHEA:11873 (Rhea) Cortisol. Cortisone. mim-conversion. RHEA:53117 (Rhea) Cortisone. ...
more infohttps://www.wikipathways.org/index.php?title=Pathway:WP4523&oldid=103290
Aldosterone and Renin | SpringerLink  Aldosterone and Renin | SpringerLink
Biglieri, E. G., and Schambelan, M., 1979, Significance of elevated levels of plasma hydroxycorticosterone in patients with ... I. Significance of 18-hydroxy-11-deoxycorticosterone, Am. J. Cardiol. 38: 814-824.PubMedCrossRefGoogle Scholar ... 18.. Chrousos, C. P., Vingerhoeds, A., Brandon, D., de Regt, J., Pugeat, M., Eli, C., Loriaux, D. L., and Lipsett, M. B., 1981 ... Sonino, N., Levine, L. S., Vecsei, P., and New, M. I., 1980, Parallelism of 1113 and 18-hydroxylation demonstrated in urinary ...
more infohttps://link.springer.com/chapter/10.1007/978-1-4684-4817-7_5
Bilateral Hyperplasia of the Adrenal Gland - Renal and Urology News  Bilateral Hyperplasia of the Adrenal Gland - Renal and Urology News
11-deoxycorticosterone and 18-hydroxycorticosterone, for example, have significant mineralocorticoid effect. Increases in serum ... 11-deoxycorticosterone or 18-hydroxycorticosterone suggest presence of an adrenal adenoma or adrenal carcinoma.(. Table 1. ) ...
more infohttps://www.renalandurologynews.com/labmed/bilateral-hyperplasia-of-the-adrenal-gland/article/614160/
Anti-C11B2 antibody [EPR10495] Recombinant (ab167413) | Abcam  Anti-C11B2 antibody [EPR10495] Recombinant (ab167413) | Abcam
In CMO-2 deficiency, aldosterone can be low or normal, but at the expense of increased secretion of 18-hydroxycorticosterone. ... Consequently, patients have a greatly increased ratio of 18-hydroxycorticosterone to aldosterone and a low ratio of ... Preferentially catalyzes the conversion of 11-deoxycorticosterone to aldosterone via corticosterone and 18- ... hydroxycorticosterone.. * Involvement in disease. Defects in CYP11B2 are the cause of corticosterone methyloxidase type 1 ...
more infohttps://www.abcam.com/c11b2-antibody-epr10495-ab167413.html
List of steroid abbreviations - Wikipedia  List of steroid abbreviations - Wikipedia
18 (1): 117-24. doi:10.1046/j.1460-9568.2003.02734.x. PMID 12859344. Labrie C, Simard J, Zhao HF, Belanger A, Pelletier G, ... 2007). "Measurement of 18-Hydroxycorticosterone During Adrenal Vein Sampling for Primary Aldosteronism". Journal of Clinical ...
more infohttps://en.wikipedia.org/wiki/List_of_steroid_abbreviations
The human fetal adrenal produces cortisol but no detectable aldosterone throughout the second trimester | SpringerLink  The human fetal adrenal produces cortisol but no detectable aldosterone throughout the second trimester | SpringerLink
18.. Xita N, Tsatsoulis A. Fetal origins of the metabolic syndrome. Ann N Y Acad Sci. 2010;1205:148-55.CrossRefPubMedGoogle ... The conversion of 11-deoxycorticosterone to aldosterone by CYP11B2 occurs via corticosterone and 18-hydroxycorticosterone as ... via the intermediate 18-hydroxycorticosterone, is only performed by CYP11B2 [42, 43, 44]. Therefore, the absence of detectable ... 18]. We have, therefore, extended our developmental study to examine the effects of maternal smoking on human fetal adrenal ...
more infohttps://link.springer.com/article/10.1186/s12916-018-1009-7
Metabolomics Workbench : Metabolite Reference Standards and Reagents : Compounds Approved for Synthesis  Metabolomics Workbench : Metabolite Reference Standards and Reagents : Compounds Approved for Synthesis
18-hydroxy-1,6,7-trideuterocortisol. HESFZGWRDUVOMS-AZFBHEKGSA-N. 2H. Steroids/bioactive lipids. RTI. synthesis in process ‡. ... 18-Hydroxycortisol. HESFZGWRDUVOMS-UKSDXMLSSA-N. unlabelled parent *. Steroids/bioactive lipids. RTI. synthesis in process *. ... 18-hydroxy-1,18,18-trideuterocortisol. HESFZGWRDUVOMS-YTTWDCMTSA-N. Steroids/bioactive lipids. RTI. synthesis in process ‡. ... 18-oxo-tetrahydrocortisol. ONUUOQCMEFWOSB-ASTGPZOCSA-N. NA. NA. Steroids/bioactive lipids. RTI. synthesis in process. ...
more infohttps://www.metabolomicsworkbench.org/standards/browse.php?sort_column=isotopic_label_type&sort_order=ASC&search_term=
Clinical Trials sub-cluster 33  Clinical Trials sub-cluster 33
18-hydroxycorticosterone, 18-hydroxycortisol, and 18-oxocortisol in the diagnosis of primary aldosteronism and its ... ... The aim of the study was to evaluate the role of serum 18-hydroxycorticosterone (s18OHB), urinary and serum 18-hydroxycortisol ...
more infohttp://www.biomedsearch.com/cluster/19/Clinical-Trials/sub-33-p6.html
Dr. Richard Auchus, Endocrinology, Dallas, TX  Dr. Richard Auchus, Endocrinology, Dallas, TX
Measurement of 18-hydroxycorticosterone during adrenal vein sampling for primary aldosteronism.. J. Clin. Endocrinol. Metab., ... Measurement of 18-hydroxycorticosterone during adrenal vein sampling for primary aldosteronism. Journal of Clinical ...
more infohttps://www.healthtap.com/experts/7070189-dr-richard-auchus
Etomidate - DrugBank  Etomidate - DrugBank
InChI=1S/C14H16N2O2/c1-3-18-14(17)13-9-15-10-16(13)11(2)12-7-5-4-6-8-12/h4-11H,3H2,1-2H3/t11-/m1/s1 ... In addition to this activity, the 18 or 19-hydroxylation of steroids and the aromatization of androstendione to estrone have ... Preferentially catalyzes the conversion of 11-deoxycorticosterone to aldosterone via corticosterone and 18- ... hydroxycorticosterone.. Gene Name. CYP11B2. Uniprot ID. P19099. Uniprot Name. Cytochrome P450 11B2, mitochondrial. Molecular ...
more infohttps://www.drugbank.ca/drugs/DB00292
Aldosterone - DrugBank  Aldosterone - DrugBank
Progestogin-skeleton / 21-hydroxysteroid / 20-oxosteroid / Pregnane-skeleton / 18-oxosteroid / 3-oxo-delta-4-steroid / 3- ... In addition to this activity, the 18 or 19-hydroxylation of steroids and the aromatization of androstendione to estrone have ... 3-oxo steroid, 11beta-hydroxy steroid, 20-oxo steroid, mineralocorticoid, 21-hydroxy steroid, C21-steroid hormone, 18-oxo ... Preferentially catalyzes the conversion of 11-deoxycorticosterone to aldosterone via corticosterone and 18- ...
more infohttps://www.drugbank.ca/drugs/DB04630
Human Metabolome Database: Showing metabocard for 17alpha,21-Dihydroxypregnenolone (HMDB0006762)  Human Metabolome Database: Showing metabocard for 17alpha,21-Dihydroxypregnenolone (HMDB0006762)
In addition to this activity, the 18 or 19-hydroxylation of steroids and the aromatization of androstendione to estrone have ... Preferentially catalyzes the conversion of 11-deoxycorticosterone to aldosterone via corticosterone and 18- ... hydroxycorticosterone. Gene Name:. CYP11B2. Uniprot ID:. P19099 Molecular weight:. 57559.62. Reactions. 17alpha,21- ... InChI=1S/C21H32O4/c1-19-8-5-14(23)11-13(19)3-4-15-16(19)6-9-20(2)17(15)7-10-21(20,25)18(24)12-22/h3,14-17,22-23,25H,4-12H2,1- ...
more infohttp://www.hmdb.ca/metabolites/HMDB06762
Human Metabolome Database: Showing metabocard for 17-Hydroxyprogesterone (HMDB0000374)  Human Metabolome Database: Showing metabocard for 17-Hydroxyprogesterone (HMDB0000374)
InChI=1S/C21H30O3/c1-13(22)21(24)11-8-18-16-5-4-14-12-15(23)6-9-19(14,2)17(16)7-10-20(18,21)3/h12,16-18,24H,4-11H2,1-3H3/t16-, ... Adult (>18 years old). Female. Adrenal hyperplasia, congenital, due to 3-beta-hydroxysteroid dehydrogenase 2 deficiency. ... Adult (>18 years old). Male. Adrenal hyperplasia, congenital, due to 3-beta-hydroxysteroid dehydrogenase 2 deficiency. ... In addition to this activity, the 18 or 19-hydroxylation of steroids and the aromatization of androstendione to estrone have ...
more infohttp://www.hmdb.ca/metabolites/HMDB0000374
  • 18 That poor man was put into the mad house . (spellcheck.net)
  • 18 January 2010 - Finnish IT consultancy Trainers' House Oyj (HEL: TRH1V) said last Friday it resolved to issue a EUR5m hybrid bond to domestic investors in a bid to strengthen its capital structure. (thefreedictionary.com)